Cholecystokinin tetrapeptide (CCK-4) has been reported to have an enhanced panicogenic effect in panic disorder . Like sodium lactateand CO 2 -induced panic, CCK-4-induced attacks are accompanied by hyperventilation and resemble the pattern of panic symptoms induced by CO 2 administration . In contrast to the "respiratory" panicogens sodium lactate and CO 2 (Coplan and Klein 1996) , CCK has been further reported to activate the hypothalamic-pituitary-adrenocortical (HPA) system (de Montigny 1989; Koszycki et al. 1996; Kellner et al. 1997) . It has been suggested that this effect is primarily pharmacological and unrelated to the experimentally-induced panic (Abelson et al. 1994) . However, in healthy control subjects, enhanced corticotropin (ACTH) and cortisol secretion has been linked recently to panic-like symptoms (Koszycki et al. 1998) .
Cholecystokinin tetrapeptide (CCK-4) has been reported to have an enhanced panicogenic effect in panic disorder . Like sodium lactateand CO 2 -induced panic, CCK-4-induced attacks are accompanied by hyperventilation and resemble the pattern of panic symptoms induced by CO 2 administration . In contrast to the "respiratory" panicogens sodium lactate and CO 2 (Coplan and Klein 1996) , CCK has been further reported to activate the hypothalamic-pituitary-adrenocortical (HPA) system (de Montigny 1989; Koszycki et al. 1996; Kellner et al. 1997) . It has been suggested that this effect is primarily pharmacological and unrelated to the experimentally-induced panic (Abelson et al. 1994) . However, in healthy control subjects, enhanced corticotropin (ACTH) and cortisol secretion has been linked recently to panic-like symptoms (Koszycki et al. 1998) .
To further characterize the role of the HPA system in experimentally-induced panic attacks in patients with panic disorder we compared ACTH and cortisol concentrations in patients with and without CCK-4-induced panic attacks.
METHODS
Twenty-four patients (nine women and fifteen men; mean age ϭ 38.1 years, SD ϭ 10.8) with a diagnosis of panic disorder but without a comorbid axis I disorder, as assessed with the Structured Clinical Interview for DSM-IV (Wittchen et al. 1997) were studied. These subjects had been medication-free for at least 10 days and had undergone thorough medical examination to rule out other illnesses, drug intake, and lifestyles that could interfere with the study. The protocol was approved by the local ethics committee for human experiments. After complete description of the study to the subjects, written informed consent was obtained.
All subjects were studied from 9:00 a.m. to 1:00 p.m. in a supine position in a soundproof room with a single bed (Kellner et al. 1995 (Kellner et al. , 1997 Ströhle et al. 1998b Ströhle et al. , 1999 . Each subject received a bolus injection of 25 g CCK-4 (Clinalfa, Laufelfingen, Switzerland) dissolved in 10 ml 0.9% saline at 11:00 a.m.. The Acute Panic Inventory (Dillon et al. 1987 ) was administered at 11:00 a.m. and 11:05 a.m. by a rater blind to the procedure; the maximum intensity during the observation period was noted. For a decision that a panic attack had occurred, an Acute Panic Inventory total score exceeding 20 and an increment of at least 14 points over the preinjection score (Dillon et al. 1987; Ströhle et al. 1998b ) was required. According to these criteria, 15 patients experienced a CCK-4-induced panic attack (mean age ϭ 37.4 years, SEM ϭ 2.6) and 9 (mean age ϭ 39.3 years, SEM ϭ 4.1) did not. On an exploratory level, no reasonable group differences were found for the mean age of onset (panickers: 26.8 years; nonpanickers: 27.2 years), severity of panic and agoraphobia (panickers: 23.8; nonpanickers: 23.2) (Bandelow 1995) , Hamilton depression scale scores (panickers: 8.5; nonpanickers: 7.3) (Hamilton 1960), Hamilton anxiety scale scores (panickers: 14.0; nonpanickers: 14.3) (Hamilton 1959,) and baseline Acute Panic Inventory scores (panickers: 4.9; nonpanickers: 6.4). The mean maximum Acute Panic Inventory score was 14.4 (SEM ϭ 2.9) in the patients without CCK-4-induced panic attacks and 28.1 (SEM ϭ 1.6) in those with such attacks.
For all patients, blood samples were taken at the time points 11:00 (baseline), 11:05, 11:10, 11:20, and 11:30 a.m. for the determination of the plasma ACTH and cortisol concentrations. ACTH plasma immunoreactivity was measured using a commercially available immunoradiometric assay (Nichols, San Juan Capistrano, CA) with a sensitivity of 4 pg/ml of plasma. Our intraand interassay coefficients of variation were below 10% at 20 pg/ml. For cortisol a commercial radioimmunoassay kit was employed (ICN Biomedicals Inc, Carson CA) with a sensitivity of 7 ng/ml of plasma. Our intraand interassay coefficients of variation were below 5% at 40 ng/ml.
For statistical comparison of the ACTH concentrations and the cortisol concentrations between the two groups and the various time points, a two-factorial analysis of variance (ANOVA) with a repeated-measures design was performed. Time was the within-subject factor (five levels) and group, i.e., patients with panic disorder with and without CCK-4-induced attacks, comprised the between-subjects factor (two levels). Main effects and interactions of these factors were tested about significance by multivariate criteria such as Wilks' lambda and its approximated F-value. Variables that contributed significantly to these effects, were identified by univariate F-tests. When significant main effects or interactions were found for a variable, tests with contrasts followed in ANOVA to locate the time points with significant differences in the means of that particular variable. Tests with contrasts at each time point were carried out for testing of the significant group mean differences in ACTH and cortisol concentrations during the observation period. To approach normality and homogeneity in the data, the variables of plasma hormonal concentrations used in the analysis were transformed with the log-transformation (x* ϭ ln[x]) before analysis. Alpha ϭ 0.05 was accepted as a nominal level of significance. To keep the type I error р 0.05, all posteriori tests (univariate F-test and tests with contrasts) were performed at a reduced level of significance (adjusted alpha according to the Bonferroni procedure).
RESULTS
Analysis of variance revealed significant main effects and interactions for ACTH concentrations (Wilks' multivariate tests of significance; effect of group (panic attack occurrence): approximated F ϭ 4.45, df ϭ 1, 22, p ϭ .046; effect of time: approximated F ϭ 8.46, df ϭ 4, 19, p ϭ .001; effect of group x time: approximated F ϭ 2.96, df ϭ 4, 19, p ϭ .046). Tests with contrasts between the various time points within each patient's group revealed that compared to baseline, ACTH concentrations were significantly increased after CCK-4 at 11:05 a.m. and 11:10 a.m. in patients without attacks (tests with contrasts; p Ͻ .05) and at 11:05, 11:10, 11:20, and 11:30 a.m. in patients with CCK-4-induced panic attacks (tests with contrasts p Ͻ .05). Furthermore, compared to the ACTH concentrations in nonpanickers, those in panickers were significantly higher at 11:05, 11:10, and 11:20 a.m. (tests with contrasts; p Ͻ .05).
For the cortisol concentrations, only a nonsignificant trend was observed for time (Wilk's multivariate tests of significance; effect of time: approximated F ϭ 2.73, df ϭ 4, 19, p ϭ .06). No significant effect of panic attack occurrence and no interaction between factors time and panic attack occurrence were found (Figure 1) . Thus, both patient groups show some increase in the cortisol concentrations with time, but this increase is not statistically significant compared to baseline. Furthermore, the differences between the two groups are not significant in all the time points, even if patients with attacks have higher concentration values than those without attacks.
DISCUSSION
The major finding of our study is that patients with panic disorder that experienced a CCK-4-induced panic attack had enhanced ACTH concentrations. On the other hand, those without an attack had a brief and less remarkable increase. Cortisol concentrations were not significantly influenced by neither CCK-4 administration nor the occurrence of panic attacks.
In contrast to the "respiratory" panicogens sodium lactate and CO 2 , CCK-4 induces short-lived panic attacks , possibly related to its rapid intravenous administration, producing very transient period of gasping respiratory stimulation and an exaggerated pituitary response with an increased secretion of ACTH. Studies investigating the role of CCK-4 as a panicogen, suggest that this agent seems to be a valid human model, satisfying at least six out of seven proposed criteria for an ideal panicogen (Guttmacher et al. 1983; van Megen et al. 1996b) . Criterium seven, i.e., drugs which are clinically ineffective in panic disorder are unable to block CCK-4 induced attacks, has been studied only in healthy volunteers (de Montigny 1989; . Like sodium lactate-and CO 2 -induced panic, CCK-4-induced attacks are blocked by antipanic treatment with antidepressants van Megen et al. 1997; Shlik et al. 1997 ) or benzodiazepines (de Montigny 1989 . Although CCK antagonists have so far failed to be effective in the treatment of panic disorder (Kramer et al. 1995) or benzodiazepine withdrawal induced anxiety (Abelson et al. 1995) , CCK-4 induced attacks are a promising strategy to elucidate the neurobiological correlates of panic disorder.
In patients with panic disorder, administration of CCK-4 has been shown to stimulate ACTH, whereas cortisol concentrations remain unaffected (van Megen et al. 1996a; Kellner et al. 1997; Shlik et al. 1997) . In healthy subjects, increased ACTH and cortisol secretion after CCK-4 administration (de Montigny 1989; Palmour et al. 1993; Koszycki et al. 1996) , and a further enhancement in subjects with panic-like symptoms (Koszycki et al. 1998 ) have been reported. Our results in patients with panic disorder indicate that CCK-4 has a nonpharmacological effect on the HPA system and suggest a physiological role of the increased ACTH concentrations in patients with CCK-4-induced panic attacks. CRH is the principal secretagogue for ACTH, which is produced in the anterior pituitary. Moreover, CRH has neurotransmitter-like properties outside the hypothalamus (Hayden-Hixson and Nemeroff 1993). CRH-containing neurons innervate noradrenergic centers in the pons (locus coeruleus) and the central nucleus of the amygdala, areas of recognized importance in anxiety and stress response (Gorman et al. 1989; Holsboer et al. 1992; Heit et al. 1997) . Furthermore, preclinical data indicate that CRH may play a role in the anxiogenic (Biro et al. 1993 ) and endocrine (Kamilaris et al. 1992 ) effects of CCK. However, it should be noted that CCK may activate pituitary ACTH secretion, not only via CRH, but also via other neurohormones such as oxytocin and vasopressin (Carter and Lightman 1987; Verbalis et al. 1986 ). The described association of CCK-4 induced panic attacks and an exaggerated pituitary ACTH response together with the known behavioral effects of CRH (for review see: Dunn and Berridge 1990; Holsboer et al. 1992; Owens and Nemeroff 1992) are in favor of CRH mediating the panicogenic activity of CCK-4 in patients with panic disorder.
In contrast to healthy control subjects (Koszycki et al. 1998) , and in line with previous reports (van Megen et al. 1996a; Kellner et al. 1997; Shlik et al. 1997 ) our patients with panic disorder seem to lack a clearly enhanced cortisol secretion after CCK-4 administration. However, certain effects on cortisol concentrations may be missed because of the limited time interval studied. Alternative explanations for this discrepancy that should be further investigated are delayed or reduced responsivity of the adrenal cortex to the ACTH stimulus. Furthermore, the anxiolytic peptide atrial natriuretic peptide (ANP) (Ströhle et al. 1997 ) has been shown to inhibit the stimulated HPA system (Kellner et al. 1992; Ströhle et al. 1998a ) and has been suggested to explain the unresponsiveness of the HPA system in lactate-induced panic attacks (Kellner et al. 1995) . Although ANP has effects on ACTH and cortisol concentrations, in view of the described increase in the pituitary-adrenocortical ratio (Ströhle et al. 1998a) , an exaggerated release of ANP during CCK-4 induced panic attacks may, at least in part, explain the dissociation of ACTH and cortisol concentrations.
It is of interest that pentagastrin, a 5-amino acid synthetic peptide, increases cortisol concentrations both in patients with panic disorder and in healthy control subjects, with the maximum occurring 20 minutes after administration (Abelson et al. 1991 (Abelson et al. , 1994 . The lack of an increase in cortisol secretion in patients with CCK-4-induced panic attacks is in line with studies of spontaneous or situational panic attacks (Cameron et al. 1987; Woods et al. 1987 ) as well as lactate-induced panic attacks (Liebowitz et al. 1985; Levin et al. 1987; Kellner et al. 1995; Ströhle et al. 1998b ). However, because ACTH concentrations were not reported in the studies of panic attacks not elicited by pharmacological challenges, the increase seen in patients with panic disorder and CCK-4-induced panic attacks leaves open the question of whether spontaneous or situationally predisposed panic attacks are accompanied by increased ACTH secretion as well.
In summary, our finding of an enhanced ACTH secretion during CCK-4-induced panic attacks in patients with panic disorder suggests that CRH may play a physiological role in these experimentally induced attacks. Together with the blunted ACTH response to CRH in patients suffering from panic disorder (RoyByrne et al. 1986; Holsboer et al. 1987) , our data give further evidence for a role of CRH in panic disorder and experimentally induced attacks. During panic attacks ACTH secretion may be enhanced despite the lack of clear effects on cortisol concentrations.
